Surgery Websites
Department of Surgery »  Faculty »  Division Chiefs »  Tobias Deuse, M.D.
Tobias Deuse, M.D.

Tobias Deuse, M.D.

Professor & Interim Chief
Division of Adult Cardiothoracic Surgery
The Julien I.E. Hoffman, M.D. Endowed Chair in Cardiac Surgery
Director, Minimally-invasive Cardiac Surgery
Surgical Director, Transcatheter Valve Program

Contact Information

Academic Office:
500 Parnassus Ave, MUW 405, Box 0118
San Francisco, CA 94143
tel: (415) 353 8195
fax:(415) 353-4716
Tobias.Deuse@ucsf.edu

Open Popup

University of Stuttgart (Germany), BS, Physics, 1994

University of Leipzig (Germany) Medical School, 1995

Julius-Maximilian-University Würzburg (Germany) Medical School, MD, 2000

Ludwig-Maximilian-University Munich (Germany) Medical School, 2001

  • University Hospital Munich-Grosshadern (Germany), Cardiac Surgery, 2001
  • University Heart Center Hamburg-Eppendorf (Germany), Cardiovascular Surgery, 2002-2007
  • Stanford University, Lung and Heart-Lung Transplantation, Fellowship Program, 2007-2009
  • UCSF Heart & Vascular Center
  • Oxidative Stress and Apoptosis
  • Pulmonary Hypertension
  • Stem Cell Immunobiology
  • Transplant Immunology
  • Vascular Biology
  • German

Tobias Deuse, M.D. is a cardiac and heart transplant surgeon internationally renowned for his pioneering work in the development of minimally-invasive techniques for mitral valve repair. 

Dr. Deuse graduated the University of Stuttgart (Germany) in 1994 with a BS in Physics, and in 2000 earned an M.D. from University of Wuerzburg. Dr. Deuse thereafter received advanced training in cardiothoracic surgery at the University Hospital Munich-Grosshadern and University Heart Center Hamburg-Eppendorf. After obtaining his board certification in Germany in 2007 as a heart surgeon, Dr. Deuse completed a surgical fellowship in Lung and Heart-Lung Transplantation at Stanford.

After returning to Germany in 2009, Dr. Deuse was appointed Director for Heart and Lung Transplantation at the University Heart Center in Hamburg. He achieved international acclaim for his development of innovative approaches to heart failure surgery, most notably minimally-invasive techniques for the implantation of ventricular assist systems. 

Dr. Deuse also demonstrated that high success rates could be achieved in mitral valve repair utilizing robotic-assisted (fully) endoscopic surgery. This minimally invasive procedure, also known as "keyhole surgery", has numerous benefits for the patient including substantially reduced post-surgical pain, shorter hospital stays, and a faster recovery and return to normal activities. 

Dr. Deuse has also been the recipient of numerous honors including election to the Board of Directors of the International Society for Heart and Lung Transplantation (ISHLT).

Dr. Deuse's research is focused on vascular biology and pathophysiology. His group was the among the first to elucdiate the novel pathways involved in the development of vascular intimal hyperplasia. Myointimal hyperplasia is a pathological process of the vascular system characterized by abnormal proliferation of smooth muscle cells of the vascular wall that leads to luminal obliteration and subsequent ischemia.

Myointimal hyperplasia may occur in patients after vessel injury during medical procedures (e.g. after balloon dilation or stent placement) or after pathological injury of the blood vessel (e.g. due to inflammation or toxic exposure). It can cause bypass graft failure and in-stent restenosis. To help prevent this and increase the success of treatments for vascular disease including coronary heart disease, his research group is working on the development of new preventive drug regimes and strategies.

Data provided by UCSF Profiles, powered by CTSI
  • Hypo-immunogenic cardiomyocytes for myocardial repair
    Sponsor:
    Sponsor ID:
    Funding Period:
    Aug 2018
    -
    Jun 2022
    Principal Investigator
  • Microgravity as model for immunological senescence and its impact on tissue stem cells and regeneration
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jun 2017
    -
    Jun 2021
    Co-Principal Investigator
MOST RECENT PUBLICATIONS FROM A TOTAL OF 122
Data provided by UCSF Profiles, powered by CTSI
  1. Hu X, Kueppers S, Kooreman N, Gravina A, Wang D, Tediashvili G, Schlickeiser S, Frentsch M, Nikolaou C, Thiel A, Marcus S, Fuchs S, Velden J, Reichenspurner H, Volk HD, Deuse T, Schrepfer S. The H-Y Antigen in Embryonic Stem Cells causes rejection in syngeneic female recipients. Stem Cells Dev. 2020 Jul 29. View in PubMed
  2. Kukreja J, Tsou S, Chen J, Trinh BN, Feng C, Golden JA, Hays S, Deuse T, Singer JP, Brzezinski M. Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation. Semin Thorac Cardiovasc Surg. 2020 May 20. View in PubMed
  3. Venado A, Kolaitis NA, Huang CY, Gao Y, Glidden DV, Soong A, Sutter N, Katz PP, Greenland JR, Calabrese DR, Hays SR, Golden JA, Shah RJ, Leard LE, Kukreja J, Deuse T, Wolters PJ, Covinsky K, Blanc PD, Singer JP. Frailty after lung transplantation is associated with impaired health-related quality of life and mortality. Thorax. 2020 08; 75(8):669-678. View in PubMed
  4. Smits JM, Gottlieb J, Verschuuren E, Evrard P, Hoek R, Knoop C, Lang G, Kwakkel-van Erp JM, Vos R, Verleden G, Rondelet B, Hoefer D, Langer F, Schramm R, Hoetzenecker K, van Kessel D, Luijk B, Seghers L, Deuse T, Buhl R, Witt C, Strelniece A, Green D, de Vries E, Laufer G, Van Raemdonck D. Impact of donor lung quality on post-transplant recipient outcome in the Lung Allocation Score era in Eurotransplant - a historical prospective study. Transpl Int. 2020 May; 33(5):544-554. View in PubMed
  5. Wang D, Tediashvili G, Hu X, Gravina A, Marcus SG, Zhang H, Olgin JE, Deuse T, Schrepfer S. A Cryoinjury Model to Study Myocardial Infarction in the Mouse. J Vis Exp. 2019 09 19; (151). View in PubMed
  6. View All Publications

 

Site Directory
    X